Financial Results (Standalone)

Quarterly Performance (Q2 FY27 vs Q2 FY26)

  • Income from Operations: ₹37,494.40 lakh (vs ₹948.12 lakh in Q2 FY26)
  • Other Income: ₹364.70 lakh (vs ₹72.98 lakh)
  • Total Income: ₹37,859.10 lakh (vs ₹1,021.10 lakh)
  • Profit Before Tax: ₹6,472.46 lakh (vs Loss of ₹242.01 lakh)
  • Current Tax Expense: ₹1,732.68 lakh (vs nil)
  • Net Profit for Period: ₹4,739.78 lakh (vs Loss of ₹242.01 lakh)
  • Basic EPS: ₹1.11 (vs negative)
  • Diluted EPS: ₹1.11 (vs negative)

Half-Yearly Performance (H1 FY27 vs H1 FY26)

  • Income from Operations: ₹65,530.62 lakh (vs ₹948.12 lakh in H1 FY26)
  • Other Income: ₹850.80 lakh (vs ₹72.98 lakh)
  • Total Income: ₹66,381.42 lakh (vs ₹1,021.10 lakh)
  • Profit Before Tax: ₹10,864.70 lakh (vs Loss of ₹245.42 lakh)
  • Current Tax Expense: ₹2,908.48 lakh (vs nil)
  • Net Profit for Period: ₹7,956.22 lakh (vs Loss of ₹245.42 lakh)
  • Basic EPS: ₹1.86 (vs negative)
  • Diluted EPS: ₹1.86 (vs negative)

Comparative Full Year Reference (FY26)

  • Income from Operations: ₹60,170.59 lakh
  • Other Income: ₹839.70 lakh
  • Total Income: ₹61,010.29 lakh
  • Profit Before Tax: ₹7,204.81 lakh
  • Current Tax Expense: ₹1,928.73 lakh
  • Net Profit for Period: ₹5,276.08 lakh
  • Basic EPS: ₹1.24
  • Diluted EPS: ₹1.24

Financial Ratios (Standalone as on 30.09.2026)

  • Revenue: ₹65,531 lakh
  • EBITDA: ₹12,429 lakh (Margin: 18.97%)
  • PBT: ₹10,865 lakh (Margin: 16.58%)
  • PAT: ₹7,956 lakh (Margin: 12.14%)

Consolidated Financial Results

Quarterly Performance (Q2 FY27)

  • Income from Operations: ₹41,108.55 lakh
  • Other Income: ₹367.20 lakh
  • Total Income: ₹41,475.75 lakh
  • Profit Before Tax: ₹6,707.11 lakh
  • Current Tax Expense: ₹1,824.48 lakh
  • Net Profit for Period: ₹4,882.63 lakh
  • Basic EPS: ₹1.14
  • Diluted EPS: ₹1.14

Half-Yearly Performance (H1 FY27)

  • Income from Operations: ₹71,876.76 lakh
  • Other Income: ₹865.50 lakh
  • Total Income: ₹72,742.25 lakh
  • Profit Before Tax: ₹11,254.33 lakh
  • Current Tax Expense: ₹3,053.47 lakh
  • Net Profit for Period: ₹8,200.86 lakh
  • Basic EPS: ₹1.91
  • Diluted EPS: ₹1.91

Financial Ratios (Consolidated as on 30.09.2026)

  • Revenue: ₹71,877 lakh
  • EBITDA: ₹13,151 lakh (Margin: 18.30%)
  • PBT: ₹11,254 lakh (Margin: 15.66%)
  • PAT: ₹8,201 lakh (Margin: 11.41%)

Balance Sheet Position (Standalone as at 30.09.2026)

  • Total Assets: ₹148,556.74 lakh (vs ₹130,588.44 lakh as at 31.03.2026)
  • Non-Current Assets: ₹41,341.83 lakh
  • Current Assets: ₹107,214.91 lakh
  • Total Equity: ₹108,360.50 lakh
  • Non-Current Liabilities: ₹17,416.53 lakh
  • Current Liabilities: ₹22,779.70 lakh
  • Paid-up Equity Share Capital: ₹42,835.29 lakh (42,835,290 equity shares of ₹10 each)

Cash Flow Statement (Standalone H1 FY27)

  • Net Cash from Operating Activities: -₹9,482.79 lakh
  • Net Cash from Investing Activities: -₹1,042.26 lakh
  • Net Cash from Financing Activities: ₹9,382.65 lakh
  • Net Decrease in Cash: -₹1,142.40 lakh
  • Cash and Cash Equivalents at end: ₹13,186.49 lakh

Management Discussion & Operational Updates

The Board of Directors reviewed and recorded the following business highlights and strategic expansions:

1. Medical Device Division: Witnessed massive jump in sales and profitability across domestic and institutional channels.

2. Manufacturing Licenses: Secured 26 additional licenses for medical device manufacturing.

3. Sickle Cell Screening: All regulatory approvals met; commercial product launch scheduled immediately following manufacturing license issuance in January 2027.

4. AI-Based Dialysis Machines: Production commenced at Bangalore facility; trials began in November 2026 across specialized healthcare centers and local Indian customers.

5. Global Exports: Export orders secured with machines in final testing stage; commercial shipments to commence from December 2026 end to UK, USA, Africa, Nepal, and Bangladesh.

6. Breast Cancer Screening Device: Cleared all regulatory approvals; launch for mass screening scheduled for January 2027.

7. Institutional Healthcare: Catered to 10,000 customers including hospitals over past two quarters; target of reaching 25,000 hospitals by March 2028.

8. CAR-T Therapy: Regulatory approval process underway; final clinical trials scheduled to commence in February 2027.

9. Gut Microbiome Testing: Products received CDSCO approval; ready for commercial market roll-out starting December 2027.

10. Third IVD Manufacturing Facility: Construction begun; slated to be operational before March 2028.

11. AI-Based Medical Devices for GPs: Suite of AI-based devices ready for clinical use by physicians and general practitioners globally starting February 2027.

12. US Subsidiary: Established 'Lords Mark Industries Inc.' in US to set up dedicated lab and manage export of complete range of IVD products and surgicals from India; sales commencing in March 2027 post US FDA approval.

13. UK Subsidiary: Secured all necessary approvals from MHRA; operations to start in February 2027 with product sales from India starting January 2027.

14. Caribbean Operations: Pathology laboratories being established through local Caribbean partners; export sales targeted for March 2027.

15. Lords Mark Microbiotech Expansion: Subsidiary crossed milestone of opening 70 laboratories and collection centres across India.

16. R&D Team: Expanded core R&D team by inducting 10 highly qualified professionals.

17. Global CAR-T Cancer Treatment: Initiated regulatory and clinical process to take proprietary CAR-T technology to US, UK, and Europe; trial reports slated for publication by December 2027 with advanced treatment centres operational by June 2028.

Audit and Compliance Details

The financial results have been reviewed by the statutory auditors, Sanjeev S Gupta & Associates (FRN: 012466C), with partner CA Prabodh Kumar Bhatia (M. No. 400319). The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 and Regulation 33 of SEBI (LODR) Regulations, 2015.

The consolidated results include four subsidiary companies:

  • Lords Mark Tech Next Pvt. Ltd. (Subsidiary Company)
  • Lords Green Energy Pvt. Ltd. (Subsidiary Company)
  • Renalyx Health Systems Pvt. Ltd. (Subsidiary Company)
  • Lords Mark Micro Biotech Pvt. Ltd. (Subsidiary Company)

Additional Information

  • The company was formerly known as Lords Mark India Limited / Kratos Energy & Infrastructure Limited
  • The financial statements prepared pursuant to NCLT Mumbai order for amalgamation with Kratos Energy & Infrastructure Limited
  • Date of transition to Ind-AS: April 1, 2028
  • Figures relating to previous year have been regrouped wherever necessary

The revised financial results and accompanying documents are available on the company's website at www.lordsmark.com.